<DOC>
	<DOCNO>NCT00075868</DOCNO>
	<brief_summary>RATIONALE : Octreotide may effective prevent control diarrhea patient undergo chemoradiotherapy anal rectal cancer . It yet know whether octreotide effective treating diarrhea . PURPOSE : This randomized phase III trial study octreotide prevent reduce diarrhea patient undergo chemoradiotherapy anal rectal cancer .</brief_summary>
	<brief_title>Octreotide Preventing Reducing Diarrhea Patients Receiving Chemoradiotherapy Anal Rectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine ability octreotide prevent incidence moderate , severe , life-threatening chemoradiotherapy-induced diarrhea ( grades 2-4 ) patient anal rectal cancer . Secondary - Compare quality life patient treat drug v placebo . - Compare number hospitalization use antidiarrheal agent ( e.g. , Imodium® ) relate diarrhea ( complication ) patient treat drug . - Compare treatment delay and/or dose reduction ( chemotherapy radiotherapy ) patient treat drug . OUTLINE : This double-blind , placebo-controlled , randomize , multicenter study . Patients stratify accord radiotherapy dose ( &lt; 50 Gy v ≥ 50 Gy ) , chemotherapy dose ( bolus vs continuous ) , gender . Patients randomize 1 2 treatment arm . - Arm I : Patients receive octreotide* intramuscularly ( IM ) 4-7 day start chemoradiotherapy day 22 ( ± 3 day ) chemoradiotherapy . - Arm II : Patients receive placebo* IM 4-7 day start chemoradiotherapy day 22 ( ± 3 day ) chemoradiotherapy . NOTE : *Patients receive total 2 injection octreotide placebo In arm , treatment continue absence unacceptable toxicity . Quality life assess baseline , completion chemoradiotherapy , 3 , 6 , 9 , 15 month start chemoradiotherapy . Patients follow 3 , 6 , 9 , 15 month start chemoradiotherapy . PROJECTED ACCRUAL : A total 226 patient ( 113 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary anal rectal cancer No metastasis beyond pelvic regional node Must schedule receive chemoradiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Liver function test &lt; 3 time upper limit normal No prior hepatic disease Renal Not specify Gastrointestinal No prior chronic acute regional enteritis No malabsorption syndrome No prior inflammatory bowel disease may exacerbate radiotherapy toxicity No grade 2 great uncontrollable diarrhea baseline No prior cholecystitis gallstone , unless cholecystectomy perform No prior incontinence stool Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled diabetes ( e.g. , fast glucose &gt; 250 mg/dL ) No prior allergy hypersensitivity study drug relate drug compound No medical condition mental impairment would preclude study treatment compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Prior chemotherapy allow Endocrine therapy At least 6 month since prior administration follow : Glucocorticoid therapy Insulin sensitizer ( e.g. , metformin , pioglitazone , rosiglitazone ) Exogenous growth hormone therapy Radiotherapy See Disease Characteristics No prior pelvic radiotherapy No prior intensitymodulated radiotherapy No concurrent radiotherapy abdominal cancer No concurrent hyperfractionated , splitcourse , intensitymodulated radiotherapy No brachytherapy prior completion external beam radiotherapy Surgery No prior abdominalperineal resection surgical procedure leave patient without function rectum No colostomy Other More 30 day since prior investigational drug No prior octreotide cancer therapyrelated diarrhea No concurrent prophylactic antidiarrheal medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>radiation enteritis</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage I anal cancer</keyword>
	<keyword>stage II anal cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>